Helixmith Co. Ltd - Asset Resilience Ratio
Helixmith Co. Ltd (084990) has an Asset Resilience Ratio of 34.83% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 084990 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2025)
This chart shows how Helixmith Co. Ltd's Asset Resilience Ratio has changed over time. See Helixmith Co. Ltd book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Helixmith Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Helixmith Co. Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩49.88 Billion | 34.83% |
| Total Liquid Assets | ₩49.88 Billion | 34.83% |
Asset Resilience Insights
- Very High Liquidity: Helixmith Co. Ltd maintains exceptional liquid asset reserves at 34.83% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Helixmith Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Helixmith Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Inti Kapuas Arowana Tbk
JK:IIKP |
Food & Tobacco | 0.11% |
|
Fantasy Network Ltd
TA:FNTS |
Food & Tobacco | 0.84% |
|
FarmStory Co. Ltd
KQ:027710 |
Food & Tobacco | 2.67% |
|
MSC Co. Ltd
KQ:009780 |
Food & Tobacco | 14.30% |
|
KC Feed Co. Ltd
KQ:025880 |
Food & Tobacco | 14.86% |
Annual Asset Resilience Ratio for Helixmith Co. Ltd (2010–2025)
The table below shows the annual Asset Resilience Ratio data for Helixmith Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 34.83% | ₩49.88 Billion ≈ $33.80 Million |
₩143.20 Billion ≈ $97.04 Million |
-16.29pp |
| 2024-12-31 | 51.12% | ₩76.11 Billion ≈ $51.58 Million |
₩148.89 Billion ≈ $100.90 Million |
+0.97pp |
| 2023-12-31 | 50.15% | ₩113.98 Billion ≈ $77.24 Million |
₩227.28 Billion ≈ $154.02 Million |
+26.07pp |
| 2022-12-31 | 24.08% | ₩61.18 Billion ≈ $41.46 Million |
₩254.06 Billion ≈ $172.17 Million |
+1.43pp |
| 2021-12-31 | 22.65% | ₩63.99 Billion ≈ $43.37 Million |
₩282.50 Billion ≈ $191.45 Million |
-12.72pp |
| 2020-12-31 | 35.37% | ₩169.13 Billion ≈ $114.62 Million |
₩478.14 Billion ≈ $324.03 Million |
-18.42pp |
| 2019-12-31 | 53.79% | ₩199.81 Billion ≈ $135.41 Million |
₩371.44 Billion ≈ $251.72 Million |
+22.18pp |
| 2018-12-31 | 31.61% | ₩89.85 Billion ≈ $60.89 Million |
₩284.24 Billion ≈ $192.62 Million |
-14.27pp |
| 2017-12-31 | 45.88% | ₩82.30 Billion ≈ $55.77 Million |
₩179.38 Billion ≈ $121.57 Million |
-31.17pp |
| 2016-12-31 | 77.05% | ₩137.18 Billion ≈ $92.96 Million |
₩178.04 Billion ≈ $120.65 Million |
+69.15pp |
| 2013-12-31 | 7.90% | ₩5.50 Billion ≈ $3.73 Million |
₩69.62 Billion ≈ $47.18 Million |
-2.40pp |
| 2012-12-31 | 10.30% | ₩7.01 Billion ≈ $4.75 Million |
₩67.99 Billion ≈ $46.08 Million |
-3.66pp |
| 2011-12-31 | 13.97% | ₩8.40 Billion ≈ $5.69 Million |
₩60.14 Billion ≈ $40.75 Million |
+13.95pp |
| 2010-12-31 | 0.01% | ₩9.57 Million ≈ $6.49K |
₩69.60 Billion ≈ $47.17 Million |
-- |
About Helixmith Co. Ltd
Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological… Read more